SYK STRYKER CORPORATION

Stryker elects Giovanni Caforio to Board of Directors

Stryker elects Giovanni Caforio to Board of Directors

Kalamazoo, Michigan, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that , M.D., Chairman and Chief Executive Officer of Bristol Myers Squibb, has been elected to its Board of Directors, effective December 1, 2020. 

“Giovanni adds extensive experience to our board as both a physician and business leader,” said Kevin Lobo, Chairman and Chief Executive Officer, Stryker. “As CEO of a leading global biopharmaceutical company, he has advanced scientific innovation that has helped improve the lives of patients. We look forward to welcoming Giovanni to our board.”

Dr. Caforio has been CEO of Bristol Myers Squibb since May 2015 and assumed the role of Chairman of the Board in May 2017. As CEO, Dr. Caforio has led the company’s focus on researching and developing transformational medicines, which includes leading portfolios in oncology, hematology, immunology and cardiovascular disease. In 2019, he oversaw the acquisition of Celgene. Dr. Caforio joined Bristol Myers Squibb in 2000 and with his background as a physician has helped to strengthen the company’s patient-focused culture. Prior to that, he spent 12 years with Abbott Laboratories in a number of leadership positions. Dr. Caforio is the Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), a trade association representing pharmaceutical companies in the United States.

“I am honored to join the Board of Directors for Stryker, a company with an impressive track record as a pioneer and leader in the medical technology space,” said Dr. Caforio. I am inspired by the company’s mission to make healthcare better and its focus on improving patient outcomes.”

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at .

Contacts

For investor inquiries please contact:

Preston Wells, Vice President, Investor Relations at 269-385-2600 or  

For media inquiries please contact:

Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385-2600 or

EN
09/11/2020

Underlying

SYKSTRYKER CORPORATION

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STRYKER CORPORATION

Free Trial
SYK STRYKER CORPORA...

Stryker Corp: 1 director

A director at Stryker Corp sold 500,000 shares at 363.439USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

SYK STRYKER CORPORATION
02/09/26 February 9, 2026 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker declares an $0.88 per share quarterly dividend

Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services i...

February 4, 2026 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker reports 2025 operating results and 2026 outlook

Stryker reports 2025 operating results and 2026 outlook Portage, Michigan, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2025: Fourth Quarter Results Reported net sales increased 11.4% to $7.2 billionOrganic net sales increased 11.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 100 bps to 30.2%Reported EPS increased 56.0% to $2.20Adjusted EPS(1) increased 11.5% to $4.47  Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitio...

January 29, 2026 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker to announce financial results for its fourth quarter and full ...

Stryker to announce financial results for its fourth quarter and full year 2025 Portage, Michigan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its fourth quarter and full year 2025 on Thursday, January 29, 2026.  A press release will be issued at approximately 4:05 p.m. ET and available at that day. The press release will include summary financial information for the company’s fourth quarter and full year that ended December 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, January 29, 2026, to discuss its fo...

January 5, 2026 1 EN
 PRESS RELEASE
Free
SYK STRYKER CORPORA...

Stryker declares an $0.88 per share quarterly dividend

Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.  “We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share,” said Kevin Lobo...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch